English
Qpex was selected to be among Top Life Science Companies to Watch in 2020
来源:BioSpace | 作者:Mark Terry | 发布时间: 2020-01-07 | 277 次浏览 | 分享到:

BioSpace (BioSpace champions the Life Sciences industry as a digital hub for news and careers.) is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018.

To come up with this list, BioSpace sorted companies into that age grouping, and they were then weighted by a number of different categories and finally ranked in a cumulative fashion, based on the points awarded for each category. These categories were: Finance, Collaborations, Pipeline and Innovation (view methodology below).


Qpex was ranked in the top 10 of the 21 companies recognized

7. Qpex Biopharma      

Points: 25                                                            
Launched: 2018
Location: San Diego, CA
Notable:                                     

Qpex Biopharma launched with a $33 million Series A financing from New Enterprise Associates and joined by Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund.

Qpex Biopharma is focused on developing new antibiotics. It acquired the preclinical-stage anti-infective assets of The Medicines Company (MDCO), including proprietary beta-lactamase inhibitor technology.

The U.S. Biomedical Advanced Research and Development Authority (BARDA) has made up to $132 million available to develop a portfolio of new antibiotics to fight drug-resistant, gram-negative infections. The original award was in 2016 to The Medicines Company for $32 million, with another $100 million available if all options to extend the partnership are exercised by BARDA.




About Qpex Biopharma

Qpex Biopharma (www.qpexbio.com) is a San Diego-based biopharmaceutical company with a pipeline of best-in-class agents addressing critical needs for treatment of infectious diseases in the inpatient and outpatient settings. Qpex was launched in 2018 with investments from New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund. The company’s scientists and clinicians have a record of deep expertise in the discovery and development of anti-infective agents, and an extensive record of working with public-private partnerships, including partnerships with the Biomedical Advanced Research and Development Authority (BARDA) that led to the first approved antimicrobial drug product under that program in 2017.